John C. Militello CPA, CPA Net Worth

The estimated Net Worth of John Militello is at least $1.73 Milhão dollars as of 16 August 2024. Mr Militello owns over 1,064 units of Rocket Pharmaceuticals Inc stock worth over $979,113 and over the last 8 years he sold RCKT stock worth over $364,113. In addition, he makes $385,783 as VP e Sr. Controller & Principal Accounting Officer at Rocket Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr CPA RCKT stock SEC Form 4 insiders trading

Mr has made over 21 trades of the Rocket Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 1,064 units of RCKT stock worth $19,684 on 16 August 2024.

The largest trade he's ever made was exercising 10,000 units of Rocket Pharmaceuticals Inc stock on 29 February 2024 worth over $125,500. On average, Mr trades about 1,315 units every 17 days since 2016. As of 16 August 2024 he still owns at least 51,451 units of Rocket Pharmaceuticals Inc stock.

You can see the complete history of Mr Militello stock trades at the bottom of the page.

Mr. John C. Militello CPA, CPA biography

John C. Militello CPA, CPA is the VP, Sr. Controller & Principal Accounting Officer at Rocket Pharmaceuticals Inc.

What is the salary of Mr CPA?

As the VP e Sr. Controller & Principal Accounting Officer of Rocket Pharmaceuticals Inc, the total compensation of Mr CPA at Rocket Pharmaceuticals Inc is $385,783. There are 7 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of $3,883,650.

How old is Mr CPA?

Mr CPA is 48, he's been the VP e Sr. Controller & Principal Accounting Officer of Rocket Pharmaceuticals Inc since . There are 7 older and 10 younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.

What's Mr CPA's mailing address?

John's mailing address filed with the SEC is C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY, NJ, 08512.

Insiders trading at Rocket Pharmaceuticals Inc

Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten, eInvestments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.

What does Rocket Pharmaceuticals Inc do?

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.

Complete history of Mr Militello stock trades at Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc executives and stock owners

Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Gaurav Shah,
  President, Chief Executive Officer, Director
• Kinnari Patel,
  Chief Operating Officer and Head of Development
• Kamran Alam,
  Senior Vice President - Finance, Principal Financial Officer
• Jonathan Schwartz,
  Chief Medical Officer
• Dr. Gaurav D. Shah,
  CEO & Director
• Kinnari Patel M.B.A., Pharm.D., PharmD, MBA,
  Pres, COO & Head of Devel.
• Jonathan Schwartz,
  Chief Medical Officer & Sr. VP of Clinical Devel.
• John C. Militello CPA, CPA,
  VP, Sr. Controller & Principal Accounting Officer
• Roderick Wong,
  Chairman of the Board
• Pedro Granadillo,
  Independent Director
• Carsten Boess,
  Independent Director
• Naveen Yalamanchi,
  Independent Director
• Gotham Makker,
  Independent Director
• David Southwell,
  Director
• Elisabeth Bjork,
  Independent Director
• John Militello,
  Principal Accounting Officer and Senior Controller
• Dr. Gayatri R. Rao J.D., M.D.,
  Chief Devel. Officer of LVV & Sr. VP
• Isabel Carmona J.D.,
  Sr. VP & Chief HR Officer
• Kevin Giordano,
  Director of Corp. Communications
• Martin L. Wilson,
  Gen. Counsel, Chief Compliance Officer & Sr. VP
• Mayur Kasetty,
  Bus. Devel. & Operations and Investor Relations Lead
• Carlos Garcia-Parada M.B.A.,
  Chief Financial Officer
• Investments, Lpwong Roderic...,
  
• Mark Andrew White,
  See Remarks
• Investments, Lpwong Roderic...,
  
• Roderickrtw Investments, Lp...,
  
• Keith Woods,
  
• Fady Ibraham Malik,
  
• Carlos Garcia Parada,
  Chief Financial Officer
• Martin Wilson,
  General Counsel
• Mikael Dolsten,
  
• Aaron Ondrey,
  Chief Financial Officer